Student-Run Organization

Founding Corporate Partner

logo-shape-trans

Vant Companies

7+
Therapeutic subsidiaries

Stage

Commercial + Clinical

Primary Areas

Immunology Rare Disease Urology

Listed

ROIV
NASDAQ Global Select

The analysts who succeed in biopharma investing are the ones who learned to read a NEJM paper and a 10-K with the same rigor. That combination is genuinely rare — and it requires deliberate training.

Roivant Sciences
Corporate Partner, Cornell BioVentures

Corporate Partner

The Most Unconventional Company in Biopharma.

Roivant Sciences is a biopharmaceutical company that builds, acquires, and develops medicines across therapeutic areas — but its model is unlike any other in the industry. Rather than building a single therapeutic empire, Roivant creates focused subsidiary companies — "vants" — each capitalized, staffed, and operated as an independent entity with Roivant's support and intellectual infrastructure behind it.

The result is a portfolio of commercial-stage and clinical-stage companies spanning immunology, urology, rare disease, gene therapy, and targeted protein degradation — each led by dedicated teams with deep domain expertise, each operating with the speed and focus of a startup and the resources of a major pharmaceutical company.

Listed on NASDAQ under the ticker ROIV, Roivant Sciences is the institutional backer and intellectual engine of the entire vant ecosystem.

NASDAQ: ROIV
Life Sciences
Multi-Vant Model
Commercial Stage
Clinical Stage
Image
Why This Partnership

The Alignment is Structural, Not Ceremonial.

Roivant's model demands a kind of analyst that is rare — one who can read biology and a balance sheet with equal fluency. Cornell BioVentures trains exactly that analyst. This partnership reflects a shared view of what rigorous life sciences investing actually requires.
01.
Scientific First-Principles
Roivant evaluates every asset from the biology up — the mechanism, the target, the clinical rationale — before any financial analysis begins. Cornell BioVentures operates the same way. That shared epistemology is the foundation of this partnership.
02.
The Vant Model as a Teaching Framework
Roivant's subsidiary model — building focused companies around individual assets — is one of the most instructive frameworks in biopharma. It demands cross-disciplinary thinking that maps directly to what we train our members to do.
03.
Recruiting Pipeline Access
Members of Cornell BioVentures are eligible for consideration for internship and full-time positions across Roivant and its vant companies — a direct pipeline from rigorous student training into one of biopharma's most distinctive institutional environments.
04.
Speaker Series Integration
Roivant scientists, investors, and operators participate in Cornell BioVentures' speaker series — providing direct exposure to how drug development, asset evaluation, and pharmaceutical company-building actually work at a professional level.
05.
Case Study & Curriculum Access
Roivant provides access to real-world frameworks, diligence methodologies, and case studies drawn from its own asset evaluation and vant creation process — directly informing the analytical training of BioVentures members.
06.
Institutional Validation
Roivant's decision to partner with Cornell BioVentures signals to the broader biopharma community — and to the students who consider applying — that this organization operates at a level of rigor consistent with professional institutional standards.